Seoul Semiconductor's World-First 'HV Opto-Semiconductor' Powers Up Global Top 4 Automakers
1.6.2026 16:00:00 EEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890), a global opto-semiconductor technology company, announced that its world's first High Voltage (HV) opto-semiconductor technology has entered mass production with four of the world's top automotive brands across the Americas, Europe, and Asia, with plans to expand supply to 10 models by the end of the year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601232986/en/
Comparison: Conventional 3V LED vs. Seoul Semiconductor 12V 'HV Opto-Semiconductor' (Figure: Seoul Semiconductor)
The technology combines micro-scaled opto-semiconductor chips capable of 12V single-chip operation — as opposed to conventional 3V LEDs — with a high-voltage (HV) driver technology. This enables a reduction of more than 10% in the number of driver-related components used in hybrid and electric vehicles, while lowering power consumption by approximately 10%, contributing to cost reduction and simplification of automotive electrical systems. Seoul Semiconductor aims to leverage this global mass production rollout as a springboard to lead 'HV Opto-Semiconductor' as the next-generation standard technology in the hybrid and electric vehicle sectors, backed by its already-secured portfolio of hundreds of HV opto-semiconductor chip patents and more than 50 HV driver patents.
Seoul Semiconductor aims to leverage this global mass production rollout as a springboard to lead next-generation standard technology in the hybrid and electric vehicle sectors. The core of 'HV Opto-Semiconductor' technology is based on a Multi-Junction P-N structure within a single chip. Conventional 3V drive systems required voltage step-down conversion by a factor of 1/100 when applied to hybrid and electric vehicles equipped with 300V high-voltage batteries. By contrast, applying a 30V HV chip reduces the voltage conversion ratio to just 1/10, significantly cutting conversion losses.
Previously, bridging such large voltage differences required multiple conversion circuits and components, resulting in substantial power loss, heat generation, and design complexity. Seoul Semiconductor's 'HV Opto-Semiconductor' technology minimizes the need for separate components, simplifying PCB design and reducing component count, while also lowering heat generation and improving durability. Compared to conventional 3V LEDs, it reduces driver costs by 20% and power consumption by 10%.
Matthew Fras, COO of North America Sales at Seoul Semiconductor, stated: "With global EV sales — including hybrids — set to surpass 20 million units this year, that number is expected to double to 40 million units in five years. As vehicles become more functionally advanced, the value of opto-semiconductors per vehicle is also projected to grow from $100 to $200, meaning the overall opto-semiconductor market will expand fourfold. We aim to significantly expand our market share through our 'HV Opto-Semiconductor' technology, with a goal of breaking into the global top 10 automotive brands by year-end, and we plan to elevate the automotive division to become the largest business unit within the Seoul Group this year."
According to the International Energy Agency (IEA), 1 in 4 (25%) new vehicles sold globally in 2025 will be hybrid or electric, with that share projected to more than double to over 2 in 5 by 2030. Global demand for automotive opto-semiconductors is also forecast to grow fourfold, driven by emerging functional requirements like stylish lighting and vehicle-to-vehicle communication (TrendForce).
About Seoul Semiconductor
Seoul Semiconductor is the world’s third-largest global optoelectronics (LED) company, specializing in LED technology for over 30 years. With the vision of "Making the world clean, healthy, and beautiful through light," it leads a new paradigm of light across various industries, including lighting, automotive, IT (such as backlighting), and its subsidiary, Seoul Viosys, which specializes in MicroLED, UV, Sensors, and Datacomm (SD).
Its groundbreaking technologies include the world’s first innovative No-wire LED technology WICOP, the SunLike LED, which replicates natural sunlight spectrum, the high-voltage LED Acrich, the ultra-bright nPola LED (10 times brighter than conventional LEDs), the RGB one-chip MicroLED WICOP Pixel, and UV sterilization technology Violeds.
Seoul Semiconductor holds an impressive portfolio of over 15,000 patents, and in the last 20 years, it has won over 100 cases in patent litigation across 8 countries. Believing that the patent system provides hope for young people and serves as a foundation for building a better world, the company is actively engaged in intellectual property protection. For more details, visit our official website (www.seoulsemicon.com or www.seoulviosys.com) and our social media channels (LinkedIn).
View source version on businesswire.com: https://www.businesswire.com/news/home/20260601232986/en/
Contacts
Seoul Semiconductor Co., Ltd.
Jinseop Jung
jjs8732@seoulsemicon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AIM Expands Life Sciences Supply Chain Capabilities and Hires New Partner, Thomas Ebel1.6.2026 16:01:00 EEST | Press release
AIM today announced the appointment of veteran pharma supply chain expert Thomas Ebel as Partner, effective June 15. Mr. Ebel brings more than 25 years of supply chain consulting experience at leading firms including CAMELOT, McKinsey, and Accenture, and will anchor a broader initiative to expand AIM’s end-to-end supply chain capabilities. According to Richard de Bakker, Statutory Director and Founder at AIM, the firm is significantly expanding its capabilities around “end-to-end” supply chain needs. “AIM is well known as a leader in supply chain development for launch, as well as optimization of existing supply chains — supporting clients in getting their finished products to patients,” said Mr. de Bakker. “We are now adding new capabilities in supply chain diagnostics and strategy, end-to-end planning optimization, supply reliability, and working capital optimization, among others. Combined with AIM’s established supply chain expertise, this expanded offering gives clients true ‘end-
Oscilloquartz delivers assured timing for mission-critical harsh environments with ruggedSync ™ Series OSA 55101.6.2026 15:00:00 EEST | Press release
Oscilloquartz today launched its ruggedSync™ Series OSA 5510, a ruggedized timing and synchronization platform engineered for defense and other harsh, mission-critical environments. Designed for deployment in tactical communications networks, mobile command centers (MCCs), aviation systems and other highly demanding operational environments, the OSA 5510 combines PTP grandmaster and NTP server functionality with synchronization assurance and resilient holdover in a compact MIL-qualified platform. Multi-band GNSS support, encrypted and authenticated timing options and environmental protection enable operation in contested and GNSS-denied environments where trusted synchronization must be maintained. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601763766/en/ Oscilloquartz’s ruggedSync™ Series OSA 5510 delivers resilient, high-precision timing for mission-critical defense networks. “Our new ruggedSync™ Series OSA 5510 exte
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy1.6.2026 15:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) submission for povetacicept, an investigational engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in adults with immunoglobulin A nephropathy (IgAN). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026. If approved, povetacicept will become the first commercialized therapy in Vertex’s emerging nephrology franchise. “The Phase 3 RAINIER trial is the largest conducted in IgAN and achieved full enrollment faster than any contemporary IgAN trial, reflecting the significant unmet need in IgAN and our urgency to bring povetacicept to patients with this serious disease,” said Nia Tatsis, Ph.D., Executive Vice President and Chief Regulatory and Quality Officer at Vertex. “With today’s FDA accepta
Winston Taylor Completes Historic Transatlantic Combination1.6.2026 14:01:00 EEST | Press release
Winston Taylor announces today that Winston & Strawn and Taylor Wessing’s U.K.-led business have officially launched as a single combined firm, creating a premier transatlantic law firm built for the needs of the businesses, people, and markets driving capital and innovation. One of the largest transatlantic firms, with more than 1,400 lawyers spanning the United States, the United Kingdom, Europe, Latin America, and the Middle East, Winston Taylor is built to meet clients’ evolving global needs for counsel. “As Winston Taylor, we are centered on a client-first approach and will be working shoulder to shoulder with our clients at the cutting edge of industry and ingenuity,” said Chairman Steve D’Amore. “With that common purpose, we are leveraging both strength and scale by integrating our teams and offices at record speed, working at pace to create a firm that is aligned, focused, and built for the day-to-day needs of our clients as well as their breakthrough moments.” Winston Taylor o
Kinaxis Appoints Kristin Russel as Chief Marketing Officer1.6.2026 14:00:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced the appointment of Kristin Russel as Chief Marketing Officer (CMO). Russel will lead Kinaxis’ global marketing organization, overseeing marketing strategy, corporate and market positioning, digital and brand marketing, communications and go-to-market initiatives. Russel will also take the main stage at Kinexions, where she will discuss practical steps organizations can take to move from decisions to outcomes in an increasingly complex operating environment. A tenured marketing executive and recognized industry leader, Russel brings deep experience scaling technology companies and building high impact brands. She joins Kinaxis from symplr, where she served as Chief Marketing Officer and led the development and execution of the company’s comprehensive marketing strategy across branding, digital and product marketing, public relations, community outreach programs, channel partne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom